Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nemtabrutinib
- Development stage
- Phase 3
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nemtabrutinib is an orally available, reversible, non-covalent small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed for the treatment of various B-cell malignancies. Unlike earlier BTK inhibitors, nemtabrutinib is effective against both wild-type and C481S mutant forms of BTK, addressing a common resistance mechanism to covalent BTK inhibitors. It works by blocking the action of BTK in malignant B cells, thereby suppressing oncogenic B-cell receptor signaling and inhibiting cancer cell growth and survival. Nemtabrutinib is being investigated in multiple clinical trials for blood cancers including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström’s macroglobulinemia, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, and Richter’s transformation[1][3][4][5][6].
- Other names
- MK-1026MK1026MK 1026ARQ 531ARQ531ARQ-531
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on nemtabrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nemtabrutinib.